LYC001
/ Liangyuan Bioscience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 30, 2025
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
(clinicaltrials.gov)
- P1/2 | N=600 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
IO biomarker • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1